translation agency

PR Newswire
ViroLogic Announces Expanded Agreement With GlaxoSmithKline to Support

April 24, 2002
SOUTH SAN FRANCISCO, Calif., April 24 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that the Company signed an expanded agreement with GlaxoSmithKline (NYSE: GSK) to use ViroLogic's proprietary HIV resistance testing technology in the Phase III clinical development of an investigational HIV protease inhibitor.

Under the terms of the agreement, GSK will use ViroLogic's PhenoSense(TM) HIV and GeneSeq(TM) HIV assays in its Phase III clinical trials to evaluate drug resistance in over 1,000 adult and pediatric patients receiving antiretroviral drug cocktails containing the investigational compound.

"We are pleased to continue our strong relationship with GSK, a world leader in HIV therapeutics," said Bill Young, ViroLogic's Chairman and Chief Executive Officer. "This relationship highlights the integral role our multiple technologies play in HIV drug development. ViroLogic is the only company that provides a complete range of HIV resistance testing for drug development today, making us a leader in this arena. As we penetrate the earlier stages of drug discovery and development, we anticipate this part of our business will continue to grow."

As recommended by the U.S. FDA Antiviral Drugs Advisory Committee, biopharmaceutical companies are using HIV resistance testing technology to enhance next-generation HIV drug development. There are currently16 approved HIV drugs and another 40 new drugs in the pipeline, all of which will require resistance testing for their development. ViroLogic's patented PhenoSense technology can be applied to new HIV drug targets and is being further modified for use in vaccine research and development.

About GSK

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline on the World Wide Web at

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine and pharmacogenomics by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines targeted at emerging drug-resistant viruses.

Certain statements in this press release are forward-looking, including statements relating to the Company's agreements with third parties. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, those related to performance or non-performance of the Company and those it contracts with under the Company's third-party agreements, whether ViroLogic's products will achieve market acceptance, whether payers will authorize reimbursement for our products, whether we will be able to expand our sales and marketing capabilities, whether the FDA or any other agency will decide to further regulate our products or services, whether we will encounter problems or delays in automating our process, whether we will successfully introduce new products using our PhenoSense technology, whether intellectual property underlying our technology is adequate, whether we are able to build brand loyalty, whether we will be able to raise sufficient capital and other risks and uncertainties detailed from time to time in our reports to the Securities and Exchange Commission, including our report on Form 10-K for the year ended December 31, 2000.